At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 234 enrolled
Drug / intervention
Tissue Plasminogen Activator (Alteplase)drug
Likely dose
Tissue Plasminogen Activator (Alteplase) 0.9 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
EXtending the Time Window for Thrombolysis in Posterior Circulation Stroke Without Early CT Signs
Second Affiliated Hospital, School of Medicine, Zhejiang University·interventional·Posted Jun 23, 2022·Updated Dec 18, 2024
In Brief
A Phase 3 clinical trial evaluating Tissue Plasminogen Activator (Alteplase) for Stroke, Acute Ischemic. Completed, enrolled 234 participants across 27 sites.
Detailed Summary
The primary hypothesis being tested in this trial is that ischemic stroke patients in posterior circulation at 4.5 - 24 hours post onset of stroke will have improved clinical outcomes when given intravenous tissue plasminogen activator (tPA) compared to standard care.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke, Acute Ischemic
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedJun 2022
Enrollment StartAug 2022
Primary CompletionAug 2024
TodayJul 2026
First PostedJun 23, 2022
Enrollment StartAug 17, 2022
Primary CompletionAug 15, 2024
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 4.0 years ago
Interventions
Tissue Plasminogen Activator (Alteplase)drug
Tissue Plasminogen Activator (Alteplase) 0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour Other Names: Actilyse Activase tPA r-tPA